Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the previous consensus statements on the management of …

Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …

Although cardiologists have long treated patients with coronary artery disease (CAD) and
concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a …

The global prevalence of obesity is increasing rapidly with an exponential rise in incidence
of type 2 diabetes mellitus in recent years.'Diabesity', the term coined to show the strong …

In December 2008, the US Food and Drug Administration issued guidance to the
pharmaceutical industry setting new expectations for the development of antidiabetes drugs …

Responding to concerns about the potential for increased risk of adverse cardiovascular
outcomes, specifically myocardial infarction, associated with certain glucose-lowering …

The restricted mean survival time (RMST) has been advocated as an alternative or a
supplement to the hazard ratio for reporting the effect of an intervention in a randomized …

Context The goal of the meta-analysis was to evaluate the effect of pioglitazone on the
primary and secondary prevention of cardiovascular diseases (CVDs) and renal adverse …

OBJECTIVE To assess the real-world cardiovascular (CV) safety for sulfonylureas (SU), in
comparison with dipeptidyl peptidase 4 inhibitors (DPP4i) and thiazolidinediones (TZD) …